The firm scrapped its £450m investment despite the government's offer of support, the government says.
CORE EARNINGS PER SHARE: Core earnings per share are expected to rise to $2.07 from $1.45 the year prior, according to the same consensus. AstraZeneca's stock is up 7.9% since the start of 2024.
In recognition of World Cancer Day 2025, AstraZeneca reaffirms its commitment to advancing early detection, innovative ...
A revival in AstraZeneca Plc shares faces a key test this week, with more likely to hinge on the drugmaker’s ability to ...
The U.K. government is defending its negotiations with AstraZeneca (AZN), after the pharmaceutical company dropped a planned $558M investment ...
AstraZeneca is asking a court to immediately stop generic drugmakers from their plans to make and sell generic forms of ...
Biopharmaceutical giant AstraZeneca has announced it is introducing advanced diagnostic testing for lung cancer in Kenya and ...
EMA's CHMP has recommended AstraZeneca's Imfinzi for approval in the EU as a single agent for limited-stage small cell lung ...